[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  6.00 0.68% 886.00 200,287 16:35:05
Bid Price Offer Price High Price Low Price Open Price
860.00 900.00 880.00 880.00 880.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -10.61 -16.00 640
Last Trade Time Trade Type Trade Size Trade Price Currency
17:05:52 O 10,000 901.00 GBX

Renalytix (RENX) Latest News

More Renalytix News
Renalytix Investors    Renalytix Takeover Rumours

Renalytix (RENX) Discussions and Chat

Renalytix (RENX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-10-26 16:11:20868.0010,00086,800.00O
2021-10-26 16:06:05870.0010,00087,000.00O
2021-10-26 16:05:52886.001,25011,075.00O
2021-10-26 15:52:50872.385,00043,618.75O
2021-10-26 15:36:43880.007,50066,000.00O
View all Renalytix trades in real-time

Renalytix (RENX) Top Chat Posts

DateSubject
26/10/2021
09:20
Renalytix Daily Update: Renalytix Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENX. The last closing price for Renalytix was 880p.
Renalytix Plc has a 4 week average price of 715p and a 12 week average price of 602p.
The 1 year high share price is 1,220p while the 1 year low share price is currently 436p.
There are currently 72,240,706 shares in issue and the average daily traded volume is 96,754 shares. The market capitalisation of Renalytix Plc is £640,052,655.16.
22/10/2021
08:50
2theduke: I use Halifax for renx and mxct. Barclays and others don’t seem to manage these shares well, in fact they don’t even offer mxct
22/10/2021
08:42
mg1982: but what brokers are you using for holding RENX? AJBell stung us with MXCT: "I’m writing to let you know about a change in dealing arrangements for MaxCyte Inc. MaxCyte Inc is a US security that is traded on the UK AIM market via a Depositary Interest (DI) and on the US Nasdaq exchange. To date we have offered online dealing in the UK DI based listing, however there are now substantially greater volumes of shares traded each day on the US Nasdaq exchange. This increased liquidity means better price outcomes can be obtained by trading directly on the US exchange, even allowing for foreign exchange currency conversion costs. To ensure we continue to obtain the best prices for our customers in this security we have now moved all trading to the US exchange. Please note however that currently there is no online or mobile app dealing available for the US exchange listing and any orders you place with us can only be placed by calling us on 0345 54 32 600 between 2.30pm and 5pm." So any other brokers who won't be so nasty other than HL? Thanks
22/10/2021
08:12
mr roper: JUdging by the anaemic response to the stock price this morning I have an inkling that in the next 12-24 mths Renx will be solely listed on the Nasdaq and delisted from Aim. Converting the ADR to a full listing would enable passive funds to invest in $rnlx, approx 40% of the whole market that we are currently missing out on. $rnlx closed at 1000p equivalent.
22/10/2021
07:43
2theduke: Renx in the ic today. I, once again enjoyed the detail investor call yesterday and remain here for another 10x on the share price. Gla httpx://www.investorschronicle.co.uk/news/2021/10/21/renalytix-on-the-brink-of-real-revenue/
21/10/2021
08:12
faz: THe normal straight bat from RENX. It is the anaylists' conference call where we'll get the meat on the bones. Looking forward to it.
15/9/2021
10:00
homebrewruss: The issue with these pre (significant) revenue companies is that the share price is particularly based on sentiment and once that's gone then a rapid fall can ensue. Hopefully we can now build a base around these levels as we await further news.
19/8/2021
10:08
red171: Brum1875 on LSE posted this yesterday In the absence of news (let’s wait and see), the -20% share price drop seems to have originated from the US. The stock got hit at the open by a -80k sale which compares to a daily average volume of 40k. It could be a forced seller or someone placing big bets in the options market. Anyway, this high volatility is typical of August time when institutional investors are on holiday and trading is mainly driven by smaller/private investors. Hence, most companies tend to avoid releasing market sensitive news at that time and prefer to wait until September to communicate. Obviously, Management have a duty to release any unexpected news, good or bad, as soon as it is known. Fingers crossed this is not the case today. Perhaps that is linked to the Tarbin Shahpuri tweet above Parian Global Management LP Investments has a chunk of smaller biotech. They have been selling down RNLX. Parian reported holding 513,816 at 30 June after having sold 319,673 that quarter. hxxps://whalewisdom.com/filer/parian-global-management-lp#tabholdings_tab_link
09/8/2021
08:00
wan: Relevant post from the EKF thread - The following is not going to set the share price on fire, but as indicated by Bio-techne, it will likely provide for 'another' sustainable long term source of revenue - Bio-Techne Corporation (TECH) Q4 2021 Earnings Call Transcript TECH earnings call for the period ending June 30, 2021. Aug 5, 2021 at 4:01PM COVID was an estimated 3% tailwind to our business in Q4 and approximately 4% tailwind for the year, including revenue from sales of the Kantaro IgG antibody serology kit. Encouragingly, there is growing interest in niche markets forming around our COVID serology assay offering, specifically as a tool to identify immunocompromised individuals that may not have the antibody response following vaccination to neutralize the virus. We expect the COVID research and diagnostics will be around for many years, particularly as new viral strains continue to emerge, making this tailwind a sustainable new layer of our product portfolio going forward. Excerpt available at Fool.com - hTTps://www.fool.com/earnings/call-transcripts/2021/08/05/bio-techne-corporation-tech-q4-2021-earnings-call/
15/6/2021
07:41
pugugly: Still burning cash but lots of dry powder - Some very impressive contracts signed at apparently good margins - No indication that I can see at a quick gkance when they might become cash flow positive or wheter the growing revenue momentum will enable them to raise further funds - if needed - at a premium to current share price. https://www.investegate.co.uk/renalytix-ai-plc--renx-/rns/financial-results-for-third-quarter-of-fy-2021/202106150700089139B/
16/1/2021
08:32
donald pond: I just can't make sense of those margins. I had in mind the basic cost was $925 a test, and while we may share a big chunk of that with third parties, surely the margin is still going to be very high?There's a chap on twitter, Dirk Gently, who was also explaining VRCI to me, he knows his stuff and that looks great.I do love the free spin off shares these companies generate. We got one VRCI share we got for each RENX one, so for anyone holding from that time you can add another 70p to the RENX share price to work out where you are.
Renalytix share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211027 00:03:54